Correlation of apelin with microalbuminuria in type 2 diabetic patients

1 International Diabetes Federation. IDF diabetes atlas. 7. Brussels: International Diabetes Federation; 2015. Search in Google Scholar

2 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107. Search in Google Scholar

3 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64-S71. Search in Google Scholar

4 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6 Search in Google Scholar

5 Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-72. Search in Google Scholar

6 Huang Z, Luo X, Liu M, Chen L. Function and regulation of apelin. APJ system in digestive physiology and pathology. J Cell Physiol. 2019;234:7796-810. Search in Google Scholar

7 Roche J, Rame C, Reverchon M, Mellouk N, Cornuau M, Guerif F, et al. Apelin (APLN) and Apelin Receptor (APLNR) in human ovary: expression, signaling, and regulation of steroidogenesis in primary human luteinized granulosa cells. Biol Reprod. 2016;95:104. Search in Google Scholar

8 Liu W, Yan J, Pan W, Tang M. Apelin/Elabela-APJ: anovel therapeutic target in the cardiovascular system. Ann Transl Med. 2020;8(5):243. Search in Google Scholar

9 Wan T, Fu M, Jiang Y, Jiang W, Li P, Zhou S. Research progress on mechanism of neuroprotective roles of Apelin-13 in Prevention and Treatment of Alzheimer’s Disease. Neurochem Res. 2021;47(2):205-17. Search in Google Scholar

10 Zhou JX, Shuai NN, Wang B, Jin X, Kuang X, Tian SW. Neuroprotective gain of Apelin/APJ system. Neuropeptides. 2021;87: 102131. Search in Google Scholar

11 Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma Apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115(7):428-32. Search in Google Scholar

12 Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, et al. LDL-cholesterol lowering increases plasma Apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-8. Search in Google Scholar

13 Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J. 2002;16(14):1853. Search in Google Scholar

14 Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7^th ed).Philadelphia: Saunders; 2005:1156-226. Search in Google Scholar

15 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228-36. Search in Google Scholar

16 Genetic basis of type 1 and type 2 diabetes, obesity, and their complications. Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC. [www.niddk.nih.gov/NR] (access 22 December 2011). Search in Google Scholar

17 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, TreacherFF, Turner RC.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. Search in Google Scholar

18 Kartal H, Comu FM, Kucuk A, Polat Y, Dursun AD, Arslan M. Effect of Apelin-13 on erythrocyte deformability during ischaemiareperfusion injury of heart in diabetic rats. Bratisl Lek Listy. 2017;118(3):133-6 Search in Google Scholar

19 Du JH, Li X, Li R, Xu L, Ma RR, Liu SF, et al. Elevation of serum Apelin-13 associated with proliferative diabetic retinopathy in type 2 diabetic patients. Int J Ophthalmol. 2014;7(6):968-73. Search in Google Scholar

20 Chen H, Li J, Jiao L, Petersen RB, Li J, Peng A, et al. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol. 2014;592(3):505-21. Search in Google Scholar

21 Castan-Laurell I, Masri B, Valet P. The apelin/APJ system as a therapeutic target in metabolic diseases. Expert Opin Ther Targets. 2019;23:215-25 Search in Google Scholar

22 Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes. 2013;62:1970-80 Search in Google Scholar

23 Hu H, He L, Li L, Chen L. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016;119:20-7 Search in Google Scholar

24 Palmer ES, Nigel I, O’Harte FPM.Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update. Clin Med Insights Endocrinol Diabetes. 2022;15:11795514221074679. Search in Google Scholar

25 Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, et al. Central apelin controls glucose homeostasisviaa nitric oxide-dependent pathway in mice. Antioxid Redox Signal. 2011;15:1477-96. Search in Google Scholar

26 Han S, Englander EW, Gomez GA, Rastellini C, Quertermous T, Kundu RK, et al. Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice. Endocrinology. 2015;156:2451-60. Search in Google Scholar

27 Zhang BH, Wang W, Wang H, YinJ, Zeng XJ. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS One. 2013;8(4):e60457. Search in Google Scholar

28 Dawood A, Abdelraof M, El Ghobashy Y. The relationship between serum apelin level and different grades of diabetic nephropathy in type 2 diabetic patients. Egypt J Obes Diabetes Endocrinol. 2017;3(1):32. Search in Google Scholar

29 Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol. 2013;304: F788-F800. Search in Google Scholar